JCM
PBYI icon

Jafra Capital Management’s Puma Biotechnology PBYI Stock Holding History

Jafra Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,598
Closed -$257K – 103
2017
Q4 		$257K Buy
+2,598
New +$291K 0.07% 82

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jafra Capital Management's PBYI Position: Q1 2018 in Review

Jafra Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 2,598 shares — an estimated $257K sold.

Jafra Capital Management first reported a position in PBYI in Q4 2017 and held it in 1 quarter. The position peaked at $257K in Q4 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Jafra Capital Management reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Jafra Capital Management sold 2,598 Puma Biotechnology shares in Q1 2018, an estimated $257K.
  • Jafra Capital Management first reported a position in Puma Biotechnology in Q4 2017 and held it in 1 quarter.
  • Jafra Capital Management's Puma Biotechnology position peaked at $257K in Q4 2017.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Jafra Capital Management's 13F filing for Q1 2018, filed 23 Apr 2018.